Detalles de la búsqueda
1.
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.
Lancet
; 399(10319): 50-59, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34921756
2.
Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors).
Rev Soc Bras Med Trop
; 56: e0565, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37075454
3.
Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial.
Signal Transduct Target Ther
; 8(1): 46, 2023 01 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36717539
4.
Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors)
Rev. Soc. Bras. Med. Trop
; 56: e0565, 2023. tab, graf
Artículo
en Inglés
|
LILACS-Express
| ID: biblio-1431408
Resultados
1 -
4
de 4
1
Próxima >
>>